Abstract
The cellular electrophysiologic effect of GYKI 16638, a new antiarrhythmic compound was studied and compared with that of sotalol and mexiletine in undiseased human right ventricular muscle preparation by applying the conventional microelectrode technique. GYKI 16638 (5 μM), at stimulation cycle length of 1000 ms, lengthened action potential duration (APD90) from 338.9 ± 28.6 ms to 385.4 ± 24 ms (n = 9, p < 0.05). This APD lengthening effect, unlike that of sotalol (30 μM), was rate-independent. GYKI 16638, contrary to sotalol and like mexiletine (10 μM), exerted a use-dependent depression of the maximal rate of depolarization (Vmax) which amounted to 36.4 ± 11.7 percent at cycle length of 400 ms (n = 5, p p < 0.05) and was characterised with an offset kinetical time constant of 298.6 ± 70.2 ms. It was concluded that GYKI 16638 in human ventricular muscle shows combined Class IB and Class III antiarrhythmic properties, resembling the electrophysiological manifestation seen after chronic amiodarone treatment.
Keywords: Antiarrhythmic, Sotalol, Mexiletine
Current Medicinal Chemistry
Title: The Cellular Electrophysiologic Effect of A New Amiodarone Like Antiarrhythmic Drug GYKI 16638 in Undiseased Human Ventricular Muscle: Comparison With Sotalol And Mexiletine
Volume: 9 Issue: 1
Author(s): M. Opincariu, A. Varro, N. Iost, L. Virag, O. Hala, J. Szolnoki, J. Szecsi, G. Bogats, P. Szenohradszky, P. Matyus and J. Gy. Papp
Affiliation:
Keywords: Antiarrhythmic, Sotalol, Mexiletine
Abstract: The cellular electrophysiologic effect of GYKI 16638, a new antiarrhythmic compound was studied and compared with that of sotalol and mexiletine in undiseased human right ventricular muscle preparation by applying the conventional microelectrode technique. GYKI 16638 (5 μM), at stimulation cycle length of 1000 ms, lengthened action potential duration (APD90) from 338.9 ± 28.6 ms to 385.4 ± 24 ms (n = 9, p < 0.05). This APD lengthening effect, unlike that of sotalol (30 μM), was rate-independent. GYKI 16638, contrary to sotalol and like mexiletine (10 μM), exerted a use-dependent depression of the maximal rate of depolarization (Vmax) which amounted to 36.4 ± 11.7 percent at cycle length of 400 ms (n = 5, p p < 0.05) and was characterised with an offset kinetical time constant of 298.6 ± 70.2 ms. It was concluded that GYKI 16638 in human ventricular muscle shows combined Class IB and Class III antiarrhythmic properties, resembling the electrophysiological manifestation seen after chronic amiodarone treatment.
Export Options
About this article
Cite this article as:
Opincariu M., Varro A., Iost N., Virag L., Hala O., Szolnoki J., Szecsi J., Bogats G., Szenohradszky P., Matyus P. and Gy. Papp J., The Cellular Electrophysiologic Effect of A New Amiodarone Like Antiarrhythmic Drug GYKI 16638 in Undiseased Human Ventricular Muscle: Comparison With Sotalol And Mexiletine, Current Medicinal Chemistry 2002; 9 (1) . https://dx.doi.org/10.2174/0929867023371517
DOI https://dx.doi.org/10.2174/0929867023371517 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
Current advances in inherited cardiomyopathy
Describe in detail all novel advances in multimodality imaging related to inherited cardiomyopathy diagnosis and prognosis. Shed light to deeper phenotypic characterization. Acknowledge recent advances in genetics, genomics and precision medicineread more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Analgesics in Pregnancy: An Update on Use, Safety and Pharmacokinetic Changes in Drug Disposition
Current Pharmaceutical Design A Tour of Unsupervised Deep Learning for Medical Image Analysis
Current Medical Imaging Recent Patents on Wireless Capsule Endoscopy
Recent Patents on Biomedical Engineering (Discontinued) The Role of Sympathetic Nervous System in the Progression of Chronic Kidney Disease in the Era of Catheter Based Sympathetic Renal Denervation
Current Clinical Pharmacology Targeting Apelinergic System in Cardiometabolic Disease
Current Drug Targets Levosimendan: From Basic Science to Clinical Trials
Recent Patents on Cardiovascular Drug Discovery Yoga can Alter the Autonomic Neural Activity: A Critical Analysis
Current Traditional Medicine Therapeutic Potential and Mechanisms of Action of Mesenchymal Stromal Cells for Acute Respiratory Distress Syndrome
Current Stem Cell Research & Therapy Novel Thioester Prodrug of N-acetylcysteine for Odor Masking and Bioavailability Enhancement
Current Drug Delivery Cardiac Tissue Engineering
Recent Patents on Regenerative Medicine Perinatal and Neonatal Outcomes of Lithium-Treated and Untreated Bipolar Women During Pregnancy: A Review of Present Literature
Current Psychopharmacology Current Issues in Intravenous Fluid Use in Hospitalized Children
Reviews on Recent Clinical Trials Cerebrovascular Complications of Diabetes: SGLT-2 Inhibitors as a Promising Future Therapeutics
Current Drug Targets Computational and Pharmacogenomic Insights on Hypertension Treatment: Rational Drug Design and Optimization Strategies
Current Drug Targets Pharmacological Strategies for Inhibition of Thrombin Activity
Current Pharmaceutical Design Proteomics Analysis Revealed an Altered Left Ventricle Protein Profile in a Mouse Model of Transverse Aortic Constriction
Protein & Peptide Letters Green Tea Attenuates Cardiovascular Remodeling and Metabolic Symptoms in High Carbohydrate-Fed Rats
Current Pharmaceutical Biotechnology Modulation of the TRPV1 Channel: Current Clinical Trials and Recent Patents with Focus on Neurological Conditions
Recent Patents on CNS Drug Discovery (Discontinued) The Role of Celecoxib as a Potential Inhibitor in the Treatment of Inflammatory Diseases - A Review
Current Medicinal Chemistry Understanding The Role of Inflammasome in Angina Pectoris
Current Protein & Peptide Science